Tofacitinib is Safe and Effective When Used in Combination With Infliximab for the Management of Refractory Ulcerative Colitis
We read with interest the article by Berinstein et al1 regarding the use of tofacitinib for the management of acute severe ulcerative colitis (UC). Janus kinase inhibitors in UC targeting multiple inflammatory pathways may offer advantages over monoclonal antibodies targeting specific cytokines;2 however, studies regarding the safety and effective ness of combination biologic and small molecule therapies in UC are limited.3,4 We herein describe the use of tofacitinib in combination with infliximab for the management of UC.
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Robert Gilmore, Patrick Hilley, Ashish Srinivasan, Matthew C. Choy, Josephine A. Grace, Peter de Cruz Tags: Letter to the Editor Source Type: research